tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Sep 2;2104527.
doi: 10.1080/21645515.2022.2104527. Online ahead of print.
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India
Nijalingappa K Kalappanavar[SUP] 1 [/SUP], Apurba Ghosh[SUP] 2 [/SUP], Monika Sharma[SUP] 3 [/SUP], Latha Ravichandran[SUP] 4 [/SUP], Nirmal Choraria[SUP] 5 [/SUP], Saravanan P[SUP] 6 [/SUP], Madhukar Pandey[SUP] 7 [/SUP], Pradeep N[SUP] 8 [/SUP], Prachee Shah[SUP] 9 [/SUP], Sneha Nair[SUP] 10 [/SUP], Ashfaque Shaikh[SUP] 10 [/SUP], Serge van de Witte[SUP] 11 [/SUP]
Affiliations
Abstract
Efficacy and safety data on quadrivalent influenza vaccines (QIVs) for immunization of Indian children are scarce. This phase 3, registration study evaluated the immunogenicity, safety, and tolerability of a QIV in Indian children aged 6-35 months (Group 1) and 3-17 y (Group 2). Subjects received one or two doses (0.5 mL each) of the study vaccine based on their priming status. Immunogenicity (post-vaccination geometric mean fold increase in hemagglutination inhibition [HI] titers and proportion of patients with seroprotection and seroconversion against the four influenza strains), unsolicited adverse events (AEs), and tolerability were analyzed. Among 118 subjects enrolled in each group, the geometric mean(standard deviation) fold increase in HI titers against A(H3N2), A(H1N1), B(Victoria), and B(Yamagata) strains were 31.7(5.33), 10.5(6.06), 4.1(5.70), and 8.6(5.34) in Group 1 and 14.0(4.37), 9.2(4.26), 14.3(6.73), and 14.4(5.41) in Group 2, respectively. Seroprotection was achieved by 91.2%, 83.3%, 41.2%, and 68.4% subjects in Group 1 and 100%, 95.8%, 73.7%, and 89.8% subjects in Group 2, respectively. Seroconversion was achieved by 87.7%, 66.7%, 41.2%, and 64.9% subjects in Group 1 and 89.0%, 78.8%, 69.5%, and 75.4% subjects in Group 2, respectively. Vaccination site pain and fever were the most common local and systemic reactions, respectively. Systemic reactions were more frequent in Group 1 (16.9% vs 7.6%). Most subjects (>90%) did not experience inconvenience within 7 d of vaccination; <10% in both groups reported unsolicited AEs. Thus, the QIV had a positive benefit/risk profile in Indian children/adolescents aged 6 months to 17 y.CTRI Registry No: CTRI/2018/05/014191Registry Name: Clinical Trials Registry - IndiaDate of Trial Registration: May 29, 2018Study Dates: August 03, 2018 (first subject first visit) to January 31, 2019 (last subject last visit)Drugs Controller General of India [DCGI] permission letter number: CT-03/2018.
Keywords: Adolescents; children; hemagglutination; immunogenicity; influenza; quadrivalent influenza vaccine; reactogenicity.
. 2022 Sep 2;2104527.
doi: 10.1080/21645515.2022.2104527. Online ahead of print.
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India
Nijalingappa K Kalappanavar[SUP] 1 [/SUP], Apurba Ghosh[SUP] 2 [/SUP], Monika Sharma[SUP] 3 [/SUP], Latha Ravichandran[SUP] 4 [/SUP], Nirmal Choraria[SUP] 5 [/SUP], Saravanan P[SUP] 6 [/SUP], Madhukar Pandey[SUP] 7 [/SUP], Pradeep N[SUP] 8 [/SUP], Prachee Shah[SUP] 9 [/SUP], Sneha Nair[SUP] 10 [/SUP], Ashfaque Shaikh[SUP] 10 [/SUP], Serge van de Witte[SUP] 11 [/SUP]
Affiliations
- PMID: 36053721
- DOI: 10.1080/21645515.2022.2104527
Abstract
Efficacy and safety data on quadrivalent influenza vaccines (QIVs) for immunization of Indian children are scarce. This phase 3, registration study evaluated the immunogenicity, safety, and tolerability of a QIV in Indian children aged 6-35 months (Group 1) and 3-17 y (Group 2). Subjects received one or two doses (0.5 mL each) of the study vaccine based on their priming status. Immunogenicity (post-vaccination geometric mean fold increase in hemagglutination inhibition [HI] titers and proportion of patients with seroprotection and seroconversion against the four influenza strains), unsolicited adverse events (AEs), and tolerability were analyzed. Among 118 subjects enrolled in each group, the geometric mean(standard deviation) fold increase in HI titers against A(H3N2), A(H1N1), B(Victoria), and B(Yamagata) strains were 31.7(5.33), 10.5(6.06), 4.1(5.70), and 8.6(5.34) in Group 1 and 14.0(4.37), 9.2(4.26), 14.3(6.73), and 14.4(5.41) in Group 2, respectively. Seroprotection was achieved by 91.2%, 83.3%, 41.2%, and 68.4% subjects in Group 1 and 100%, 95.8%, 73.7%, and 89.8% subjects in Group 2, respectively. Seroconversion was achieved by 87.7%, 66.7%, 41.2%, and 64.9% subjects in Group 1 and 89.0%, 78.8%, 69.5%, and 75.4% subjects in Group 2, respectively. Vaccination site pain and fever were the most common local and systemic reactions, respectively. Systemic reactions were more frequent in Group 1 (16.9% vs 7.6%). Most subjects (>90%) did not experience inconvenience within 7 d of vaccination; <10% in both groups reported unsolicited AEs. Thus, the QIV had a positive benefit/risk profile in Indian children/adolescents aged 6 months to 17 y.CTRI Registry No: CTRI/2018/05/014191Registry Name: Clinical Trials Registry - IndiaDate of Trial Registration: May 29, 2018Study Dates: August 03, 2018 (first subject first visit) to January 31, 2019 (last subject last visit)Drugs Controller General of India [DCGI] permission letter number: CT-03/2018.
Keywords: Adolescents; children; hemagglutination; immunogenicity; influenza; quadrivalent influenza vaccine; reactogenicity.